Reproduction of Transfusion-Related Acute Lung Injury in an Ex Vivo Lung Model

By Werner Seeger, Udo Schneider, Bettina Kreusler, Esther v. Witzleben, Dieter Walmrath, Friedrich Grimminger, and Jürgen Neppert

Leukoagglutinins are implicated in transfusion-related acute lung injury (TRALI). In the present study, severe lung vascular leakage was reproduced by application of a leukoagglutinating antibody of anti-5b specificity in an ex vivo lung model. The antibody originated from a multiparous donor-plasma, observed to cause noncardiogenic edema during transfusion therapy. Heated full plasma (anti-5b-titer 1/128) or purified immunoglobulin G fraction was used for the studies. Ex vivo isolated rabbit lungs were perfused with albumin buffer, and human granulocytes (PMN) were admixed to the recirculating perfusate. In presence of anti-5b antibody plus 5b-positive PMN plus rabbit plasma as complement-source, severe lung edema occurred after a latent period of 3 to 6 hours. Pulmonary artery pressure was only transiently and moderately increased, and the leakage reaction could be traced back to a several-fold increase in lung vascular permeability. In contrast, no vascular leakage was noted in lungs perfused in the absence of anti-5b antibody, PMN, or rabbit plasma. Moreover, no permeability increase occurred on use of 5b-negative PMN. This reproduction of TRALI in an ex vivo lung model corroborates the role of leukoagglutinating antibodies in initiating PMN-dependent respiratory distress and suggests a contribution of concomitant complement activation.

NONCARDIOGENIC pulmonary edema after transfusion therapy is an infrequent but hazardous complication.1-3 The occurrence of this entity, characterized as transfusion-related acute lung injury (TRALI), is linked to the presence of circulating leukoagglutinins. Clinical features include chills, fever, tachycardia, cough, and various degrees of respiratory distress. Transient leukopenia may be noted.4 The chest x-ray demonstrates bilateral pulmonary infiltrates in the absence of cardiac enlargement and pulmonary vascular engorgement.5-11 Normal pulmonary capillary wedge pressure on right heart catheterization verifies the “noncardiogenic” origin of the pulmonary edema formation.12,13,16-18 The onset of respiratory distress ranges between a few minutes19,20 and 40 hours21 after transfusion, with a maximum at 4 to 8 hours. In most cases, the symptoms subside within 1 or 2 days with full recovery.

The underlying mechanisms of TRALI are not fully understood. Initiation is attributed to passive transfer of donor antibodies against leukocytes2-3,14,16-18 or, more rarely, presence of leukoagglutinins in the recipient serum.2,3,7,18 Leukocyte antibodies of different specificity have been implicated. These include HLA-related antibodies12,14,18,19 and granulocyte-specific antibodies (i.e., anti-NA,4); however, a positive cause and effect relationship could not conclusively be established in all cases. In addition, antibodies against the diallelic (5a/5b) group five antigen system, assumed to be present on granulocytes, lymphocytes, and platelets,20-22 have been associated with onset of nonhemolytic febrile transfusion reactions.23 Plasma containing agglutinating immunoglobulin G (IgG) antibody of anti-5b specificity was recently described to induce acute respiratory distress after transfusion.15 This is noteworthy, as more than 80% of the western population express the 5b-epitope on their polymorphonuclear leukocytes (PMN), and particularly multiparous 5b-negative women were noted to develop significant anti-5b antibody titers.24,25 In accordance with this notion, the cause of a recent transfusion-related lung edema in the Blood Center of the University of Giessen (FRG) could be traced back to a high anti-5b titer in the donor plasma, originating from a multiparous woman. In the present study, performed in an established model of blood-free perfused rabbit lungs, we reproduced acute lung injury by intravascular administration of this antibody, 5b-positive PMN, and rabbit plasma as complement source. This mimicry of TRALI in an ex vivo model will allow further elucidation of underlying mechanisms resulting in the development of severe lung vascular leakage in this syndrome.

MATERIALS AND METHODS

Ex vivo lung preparation. The model of isolated rabbit lungs has been previously described26 (Fig 1). Briefly, rabbits of either sex (body weight 2.3 to 2.8 kg) were deeply anesthetized with pentobarbital (60 to 90 mg/kg) and anticoagulated with 1,000 U/kg heparin. Tracheotomy and thoracotomy were performed and lungs were excised while being ventilated and perfused. A gas mixture of 4% CO2, 17% O2, and 79% N2 was used. The lungs were perfused via cannulas in the pulmonary artery and the left ventricle with Krebs Henseleit albumin (1% wt/vol) buffer (KHAB) with a constant pulsatile flow of 100 mL/min (total recirculating volume 250 mL). The use of two different perfusion circuits allowed repeated exchange of perfusion fluid by fresh buffer medium. The lungs were placed in a 38°C equilibrated chamber, freely suspended from a force transducer. Pulmonary arterial pressure (PAP), pulmonary venous pressure (PVP), ventilation pressure (VP), and the weight of the isolated organ were continuously registered. A left atrial pressure of 2 mm Hg ensured zone III conditions at endexpiration. The capillary filtration coefficient (Kfc) and the total vascular compliance (COM) were repeatedly determined from the slope of weight gain, induced by a sudden venous pressure elevation (hydrostatic challenge maneuver) of 10 cm H2O for 8 minutes (gravimetric technique). Zero time extrapolation of the slope of weight gain by

© 1990 by The American Society of Hematology.
MODEL OF TRANSFUSION-RELATED LUNG INJURY

Preparation of anti-5b-containing human plasma and its IgG fraction. The antibody specificity as anti-5b IgG was determined with the generous support of donors and reagents by Dr F.H.J. Claas (Leiden, The Netherlands). The titer of the anti-5b antibody was 1/128. The plasma of the donor with high anti-5b titer (1/128) was obtained by plasmapheresis and heated for 30 minutes at 57°C to inactivate complement factors. IgG was fractionated purified by ionic exchange chromatography, using a DEAE 32 column. Plasma, 89 mL, yielded an IgG-eluate of 29 mL in 0.9% saline with a protein concentration of 1.66 g/100 mL and a leukaagglutinating titer of 1/64.  

Analytical procedures. Thromboxane A2 (TxA2) and prostacyclin (PGI2) were assayed serologically from the recirculating buffer fluid as their stable hydrolysis products TxB2 and 6-keto PGF1α. The method has been previously described. Leukotriene (LT) B4, omega-oxidation products of LTBD2, 5-hydroxyicosatetraenoic acid (5-HETE), and nonenzymatic hydrolysis products of LTA4 in PMN stimulated in vitro were assayed as described.  

Experimental protocol. After an isogravimetric steady-state period of 45 minutes, perfusate was exchanged, time was set zero, and the first hydrostatic challenge was immediately performed in all lung experiments (Kfc 0 minutes). In the standard protocol, the perfusate medium was next exchanged by Khab with 15% (vol/vol) rabbit plasma and 4% (vol/vol) anti-5b containing human plasma. In a subgroup of the standard protocol, the antibody-containing human plasma was replaced by the purified antibody-containing IgG fraction to give a corresponding anti-5b-titer in the recirculating perfusate. A second hydrostatic challenge was performed (Kfc 15'), and 2 × 107 PMN were injected directly into the pulmonary artery in a total volume of 2-mL buffer fluid. Three and fifteen minutes after PMN application, the circulating leukocytes were 30 ± 4 and 25 ± 5/μL in the lung effluent, documenting a nearly quantitative sequestration of the PMN in the pulmonary vascular bed, as previously described.  

Subsequent hydrostatic challenges were performed at 30, 45, 60, 120, 180, and 360 minutes. Control experiments included those with (1) use of 5b-negative PMN (AB-PMN+ in Table 1); (2) absence of PMN (AB+PL in Table 1); (3) replacement of anti-5b-containing plasma by heated human plasma without significant antibody titer (PL + PMN in Table 1); (4) omission of rabbit plasma (AB+PMN). Exchange of perfusate and hydrostatic challenges in these experiments were performed according to the standard protocol. Perfusion samples, of 2 mL for detection of prostanoids (TxA2 and PGI2) were taken according to the time schedule in Table 2.  

In addition to in vitro experiments, 4 × 106 PMN (5b-negative or -positive) were incubated at 37°C in a total volume of 5-mL buffer fluid, in the absence or presence of anti-5b containing plasma and/or rabbit plasma. Cells were centrifuged after 30 or 90 minutes, and the supernatant was analyzed for leukotrienes and 5-HETE.  

Materials. Bovine albumin (92% purity, reduced in free fatty acids to <5 μg/g) was purchased from Paesel GmbH (Frankfurt, FRG). TxB2, were graciously supplied by Ono Pharmaceutical (Osaka, Japan). 6-Keto-PGF1α, was obtained from Sigma GmbH (Munich, FRG), and rabbit anti-6-keto-PGF1α, as well as anti-TxB2, were purchased from Paesel GmbH. Triluated 6-keto-PGF1α (120 to 180 Ci/mmol) and TxB2 (100 to 150 Ci/mmol) were obtained from New England Nuclear GmbH (Dreieich, FRG). RPMI 1640 medium and fetal calf serum were from Boehringer Mannheim GmbH (Mannheim, FRG), and Percoll from Pharmacia Fine Chemicals (Uppsala, Sweden). All others biochemicals were obtained from Merck (Munich, FRG).  

Statistical methods. Values are given as mean ± standard deviation (SD). Data were analyzed by two-way analysis of variance.
RESULTS

Under baseline conditions, pulmonary artery pressure, ventilation pressure, Kfc-data, and lung weight of all lungs ranged at normal values, corresponding to previous isolated lung studies. Application of anti-5b antibody, 5b-positive human PMN, and rabbit plasma as complement source in the standard protocol caused a transient, moderate increase in pulmonary artery pressure (Table 1). The total pressure rise averaged ~5 mm Hg, with a maximum at about 45 to 120 minutes. At the end of experiment (360 minutes), baseline pulmonary artery pressure was reached again. However, the outstanding biophysical alteration in this group was a delayed, severe increase in lung vascular permeability (Fig 2, Table 3). The Kfc values determined after 180 minutes ranged at a slightly increased level (~2 mL per cm H2O per gram wet lung weight per second × 10−4), and the hydrostatic challenge-induced weight gain was moderately augmented (~2.5 g). In the subsequent 180-minute perfusion

Table 1. PAP and COM in the Absence or Presence of Anti-5b Antibody Rabbit Plasma, and 5b-Positive or 5b-Negative Granulocytes

<table>
<thead>
<tr>
<th>Variables</th>
<th>Groups</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>50</th>
<th>60</th>
<th>120</th>
<th>180</th>
<th>360</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAP*</td>
<td>AB + PMN5b + PL†</td>
<td>± 0.57</td>
<td>± 0.46</td>
<td>± 0.37</td>
<td>± 0.28</td>
<td>± 0.20</td>
<td>± 0.12</td>
<td>± 0.07</td>
<td>± 0.02</td>
<td>± 0.00</td>
</tr>
<tr>
<td></td>
<td>AB + PL</td>
<td>± 0.00</td>
<td>± 0.05</td>
<td>± 0.07</td>
<td>± 0.07</td>
<td>± 0.05</td>
<td>± 0.03</td>
<td>± 0.02</td>
<td>± 0.01</td>
<td>± 0.00</td>
</tr>
<tr>
<td></td>
<td>PL + PMN5b</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
<td>± 0.35</td>
</tr>
<tr>
<td>COM§</td>
<td>AB + PMN5b + PL†</td>
<td>± 0.50</td>
<td>± 0.45</td>
<td>± 0.40</td>
<td>± 0.35</td>
<td>± 0.30</td>
<td>± 0.25</td>
<td>± 0.20</td>
<td>± 0.15</td>
<td>± 0.10</td>
</tr>
<tr>
<td></td>
<td>AB + PL</td>
<td>± 0.04</td>
<td>± 0.08</td>
<td>± 0.12</td>
<td>± 0.16</td>
<td>± 0.20</td>
<td>± 0.24</td>
<td>± 0.30</td>
<td>± 0.35</td>
<td>± 0.40</td>
</tr>
<tr>
<td></td>
<td>PL + PMN5b</td>
<td>± 0.54</td>
<td>± 0.58</td>
<td>± 0.62</td>
<td>± 0.66</td>
<td>± 0.70</td>
<td>± 0.74</td>
<td>± 0.78</td>
<td>± 0.82</td>
<td>± 0.86</td>
</tr>
</tbody>
</table>

Abbreviations: AB, anti-5b antibody; PL, rabbit plasma; PMN5b, 5b-positive granulocytes; PMN−, 5b-negative granulocytes.

†This group includes n = 3 experiments with anti-5b antibody containing human plasma and n = 2 experiments with purified IgG fraction.

‡This group includes n = 2 experiments with autologous PMN taken from the antibody donor and n = 2 experiments with 5b-negative PMN obtained from a different donor.

§The vascular compliance (COM) gives the change in vascular volume per change in microvascular pressure (mL/cm H2O).

Table 2. Perfusate 6-keto-PGF1α Concentrations Detected in the Absence or Presence of Anti-5b Antibody, Rabbit Plasma, and 5b-Positive or 5b-Negative Granulocytes

<table>
<thead>
<tr>
<th>Groups</th>
<th>10</th>
<th>20</th>
<th>30</th>
<th>50</th>
<th>70</th>
<th>110</th>
<th>180</th>
<th>360</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB + PMN5b + PL*</td>
<td>394.6</td>
<td>386.9</td>
<td>435.4</td>
<td>547.4</td>
<td>668.5</td>
<td>574.3</td>
<td>740.4</td>
<td>1681.0</td>
</tr>
<tr>
<td>n = 5</td>
<td>± 100.7</td>
<td>± 88.2</td>
<td>± 93.7</td>
<td>± 180.0</td>
<td>± 444.7</td>
<td>± 122.5</td>
<td>± 338.2</td>
<td>± 626.5</td>
</tr>
<tr>
<td>AB + PMN− + PL†</td>
<td>302.3</td>
<td>398.2</td>
<td>456.1</td>
<td>583.6</td>
<td>684.5</td>
<td>691.0</td>
<td>763.4</td>
<td>762.0</td>
</tr>
<tr>
<td>n = 4</td>
<td>± 187.8</td>
<td>± 234.3</td>
<td>± 293.7</td>
<td>± 351.7</td>
<td>± 289.0</td>
<td>± 388.0</td>
<td>± 375.5</td>
<td>± 377.4</td>
</tr>
<tr>
<td>AB + PL</td>
<td>198.0</td>
<td>282.2</td>
<td>234.5</td>
<td>268.0</td>
<td>261.3</td>
<td>310.2</td>
<td>343.0</td>
<td>863.0</td>
</tr>
<tr>
<td>n = 2</td>
<td>± 57.9</td>
<td>± 61.0</td>
<td>± 63.6</td>
<td>± 2.2</td>
<td>± 12.7</td>
<td>± 43.8</td>
<td>± 4.94</td>
<td>± 102.5</td>
</tr>
<tr>
<td>PL + PMN5b</td>
<td>104.0</td>
<td>113.2</td>
<td>168.5</td>
<td>282.0</td>
<td>396.0</td>
<td>460.9</td>
<td>607.0</td>
<td>607.0</td>
</tr>
<tr>
<td>n = 3</td>
<td>± 31.6</td>
<td>± 42.8</td>
<td>± 77.8</td>
<td>± 141.4</td>
<td>± 150.8</td>
<td>± 322.3</td>
<td>± 214.0</td>
<td>± 213.8</td>
</tr>
<tr>
<td>AB + PMN5b</td>
<td>200.0</td>
<td>227.2</td>
<td>196.0</td>
<td>262.6</td>
<td>289.3</td>
<td>391.0</td>
<td>552.3</td>
<td>648.0</td>
</tr>
<tr>
<td>n = 4</td>
<td>± 212.0</td>
<td>± 251.0</td>
<td>± 207.0</td>
<td>± 26.1</td>
<td>± 75.6</td>
<td>± 125.0</td>
<td>± 240.1</td>
<td>± 104.0</td>
</tr>
</tbody>
</table>

See Table 1 for abbreviations. 6-keto-PGF1α levels in the perfusate samples taken at various times are given for the different groups in picograms per milliliter. Responsible baseline values in differently composed perfusion fluids, analyzed before recirculation in the lungs, have been subtracted.

*This group includes n = 3 experiments with anti-5b antibody containing human plasma and n = 2 experiments with purified IgG fraction.

†P < 0.01 compared with all control groups.

‡This group includes n = 2 experiments with autologous PMN taken from the antibody donor and n = 2 experiments with 5b-negative PMN obtained from a different donor.
Fig 2. Repetitive hydrostatic challenge maneuvers induced in a lung undergoing standard protocol (A) as well as two control experiments (B and C). The original registrations of weight gain (ΔW) evoked by 10 cm H₂O sudden venous pressure elevations are given for selected time points (time scale interrupted). The controls include an experiment with use of 5b-negative PMN (B) and a study with omission of rabbit plasma (C). The protracted increase in lung weight and the several-fold increased steepness of fluid filtration induced by the 360-minute hydrostatic challenge in the standard protocol (A) are evident. The dotted line indicates baseline reset to allow continued registration of weight in this experiment.

period, performed in the absence of venous challenge, an additional lung weight gain of 2.59 ± 2.55 g was noted. The venous pressure elevation performed after 360 minutes demasked a virtually 10-fold increase in the capillary filtration coefficient in all lungs, accompanied by a several-fold rise in hydrostatic challenge-induced lung weight gain. As vascular compliance was not altered (Table 1), no significant capillary recruitment (increase in capillary surface) occurred, and the increase in Kfc must be ascribed to a several-fold increase in lung microvascular hydraulic conductivity. Onset and extent of vascular leakage did not differ between lungs in which anti-5b-containing full human plasma

Table 3. Kfc and Hydrostatic Challenge-Induced Weight Gain (ΔW) in the Absence or Presence of Anti-5b Antibody, Rabbit Plasma, and 5b-Positive or 5b-Negative Granulocytes

<table>
<thead>
<tr>
<th>Variables</th>
<th>Groups</th>
<th>0</th>
<th>15</th>
<th>30</th>
<th>45</th>
<th>60</th>
<th>90</th>
<th>120</th>
<th>180</th>
<th>360</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kfc</td>
<td>AB + PMN + PL†</td>
<td>1.89 ± 0.52</td>
<td>1.66 ± 0.36</td>
<td>1.64 ± 0.40</td>
<td>1.39 ± 0.40</td>
<td>1.32 ± 0.36</td>
<td>1.85 ± 0.98</td>
<td>2.04 ± 0.83</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kfc</td>
<td>AB + PMN + PL§</td>
<td>1.69 ± 0.95</td>
<td>1.20 ± 0.11</td>
<td>1.03 ± 0.18</td>
<td>1.11 ± 0.05</td>
<td>1.14 ± 0.87</td>
<td>1.85 ± 0.65</td>
<td>1.64 ± 0.42</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔW</td>
<td>AB + PL</td>
<td>1.41 ± 0.51</td>
<td>0.79 ± 0.11</td>
<td>1.18 ± 0.16</td>
<td>1.26 ± 0.05</td>
<td>0.98 ± 0.87</td>
<td>1.09 ± 1.65</td>
<td>1.62 ± 1.37</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔW</td>
<td>PL + PMN + 5b</td>
<td>1.41 ± 0.30</td>
<td>1.51 ± 0.47</td>
<td>1.37 ± 0.47</td>
<td>1.48 ± 0.16</td>
<td>1.31 ± 0.47</td>
<td>1.78 ± 0.47</td>
<td>1.79 ± 0.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ΔW</td>
<td>AB + PMN + 5b</td>
<td>1.94 ± 0.55</td>
<td>0.92 ± 0.62</td>
<td>1.18 ± 0.07</td>
<td>1.03 ± 0.41</td>
<td>0.88 ± 0.44</td>
<td>1.11 ± 0.59</td>
<td>1.62 ± 0.78</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>n = 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

See Table 1 for abbreviations.

†The capillary filtration coefficient is expressed in cm² per second per cm H₂O per g wet lung weight × 10⁻⁴.

‡This group includes n = 3 experiments with anti-5b antibody containing human plasma and n = 2 experiments with purified IgG fraction.

§This group includes n = 2 experiments with autologous PMN taken from the antibody donor and n = 2 experiments with 5b-negative PMN obtained from a different donor.

ΔW gives the total weight gain per hydrostatic challenge in grams.
was applied and lungs with administration of purified IgG fraction. The ventilation pressure was not altered until the 360 minute hydrostatic challenge; only in parallel with the severe edema formation during this challenge a moderate increase occurred.

In all control experiments in which PMN were administered, a transient, moderate increase in pulmonary artery pressure was noted, corresponding to that observed in the standard protocol (Table 1). In contrast, no permeability increase was observed on omission of anti-5b antibody, rabbit plasma, or PMN (Table 3). The same was true for the use of 5b-negative PMN, whether taken from the anti-5b antibody donor or obtained from a different donor with granulocytes not expressing this epitope. The KfC values remained virtually unchanged throughout the 6-hour experimental procedure. Ventilation pressure was unchanged in these lungs.

In all isolated lung experiments, a progressive accumulation of 6-keto-PGF1α in the recirculating buffer medium was noted (Table 2). This increase was significantly more pronounced in the standard experiments than in the control studies (Table 2). TxB2 ranged below 100 pg/mL in the perfusat samples of all isolated lung experiments.

Incubation of PMN in vitro resulted in marked generation of LTB4, omega-oxidation products of LTB4, nonenzymatic hydrolysis products of LTA4, and 5-HETE in the presence of anti-5b and rabbit plasma as complement source, but not in appropriate controls (Table 4).

**DISCUSSION**

In the present study, the key events of transfusion-related acute lung injury were reproduced in an ex vivo isolated lung model. The reaction was dependent on both 5b-positive PMN and antibody with anti-5b specificity, as well as rabbit plasma as complement source.

The outstanding biophysical alteration noted in the present experiments was an increase in lung vascular permeability, which exhibited delayed onset (approximately 3 hours), but progressed to severe vascular leakage toward the end of the 6-hour observation period. This reaction was dependent on the following: (1) 5b-expressing granulocytes. No permeability increase occurred in the absence of human PMN or use of autologous PMN or 5b-negative PMN of a different donor. (2) Antibody of anti-5b specificity. The vascular leakage was induced by use of the full donor plasma (antibody titer 1/128) as well as corresponding amounts of the purified IgG-fraction, but was absent on application of control plasma without significant anti-5b titer. These data corroborate the notion that receptor-occupancy on granulocytes with leukoagglutinating antibody represents the initiating event in TRALI. The presently used donor plasma volume (10 mL in a recirculating buffer volume of 250 mL, i.e., 4% vol/vol) ranges at the lower scale of donor plasma/recipient plasma relationship under clinical conditions of transfusion-associated reactions. Moreover, the ratio of applied granulocytes (2 × 10⁶) to rabbit lung capillary surface area in the present study was even lower than the ratio of circulating PMN count to lung surface area in normal human beings. Thus, "realistic" conditions for mimicy of TRALI were used, even considering the relatively high strength of anti-5b titer of the presently available donor plasma.

It is noteworthy that in addition to 5b-positive PMN and anti-5b antibody, rabbit plasma as complement source was necessary for establishing the vascular leakage response. Nonheated human plasma could not be applied for this purpose, as the human complement system is known to be spontaneously activated at rabbit cell surfaces via the alternate pathway. Additional controls with heated rabbit plasma (data not given) supported the notion that the integrity of the complement system was necessary for initiation of the anti-5b- and PMN5b-dependent lung vascular injury. This is a surprising observation in view of the fact that anti-5b specific antibodies, including the one presently used, induce leukoagglutination in a complement-independent manner and are, per se, noncytotoxic. This notion is reinforced by morphometric studies, which strongly suggest that the presently used number of neutrophils would not be sufficient to occlude substantial percentages of the large lung microvascular bed .

**Table 4. Arachidonic Acid Lipoygenase Products Released From PMN in the Presence of Anti-5b Antibody and Rabbit Plasma In Vitro**

<table>
<thead>
<tr>
<th>PMN5b</th>
<th>AB + PL (n = 4)</th>
<th>PMN</th>
<th>AB + PL (n = 4)</th>
<th>PMN5b</th>
<th>AB (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>30 min</td>
<td>90 min</td>
<td>30 min</td>
<td>90 min</td>
<td>30 min</td>
</tr>
<tr>
<td>PMN5b</td>
<td>4.2 ± 10.1</td>
<td>22.4 ± 6.3</td>
<td>24.5 ± 5.2</td>
<td>32.7 ± 4.3</td>
<td>14.3 ± 4.1</td>
</tr>
<tr>
<td>PMN5b</td>
<td>3.8 ± 2.1</td>
<td>3.2 ± 1.1</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>4.2 ± 2.2</td>
</tr>
<tr>
<td>PMN5b</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;3</td>
</tr>
<tr>
<td>PMN5b</td>
<td>&lt;3</td>
<td>&lt;3</td>
<td>&lt;5</td>
<td>&lt;5</td>
<td>&lt;3</td>
</tr>
</tbody>
</table>

PMN, 4 × 10⁶, were incubated in 5-mL buffer fluid with or without anti-5b antibody containing human AB, as well as with or without rabbit plasma (PL). The concentrations of AB and PL in these in vitro experiments correspond to those in the perfused lung studies. 5b-negative PMN (PMN5b) included two experiments with autologous PMN taken from the antibody donor and two experiments with cells from a different 5b-negative donor. All values are given as pmol/10⁶ PMN (mean ± SEM).

*a* LTB4 includes 20-OH-LTB4 and 20-COOH-LTB4.

†LTA4 decay products include the 6-transdiastereomeric pair of LTB4 and 5,6-diHETEs.
system (data not given in detail). Thus, several aspects of neutrophil activation, all implicated in the triggering of microvascular disturbances, may underlie the mimicry of TRALI in the presently used isolated lung preparation and need further elucidation. Moreover, complement activation occurring at sites of PMN antigen-antibody reaction in direct vicinity of microvascular endothelial cells (conditions of vascular sticking) might attack endothelial cell membranes. The significantly increased PGI₂ generation in the anti-5b-PMN5b system might correspond to the induction of PGI₂ generation noted after membrane insertion of the terminal complement complex in cultured lung endothelial cells. 39 This speculative view is further supported by the recent finding that in situ complement activation in the lung microvasculature causes severe vascular leakage with similarly delayed kinetic as presently noted after administration of anti-5b and PMN5b. 36 Initiation, extent, and location of concomitant complement activation, whether causing activation of neutrophils, of endothelial cells, or both, thus might represent an important variable of leukoagglutinin-induced acute lung injury. 4,5

The onset of vascular leakage was preceded by a transient lung vasoconstrictor response. However, this was comparable in all lungs with application of human PMN and thus is not specifically related to the anti-5b-PMN5b system. The absence of any significant thromboxane levels in the perfusate strongly argues against a contribution of lung thromboxane generation in this pressor response. This is noteworthy, as a large variety of soluble and particulate stimuli are known to cause pulmonary artery pressure increase via induction of this vasoconstrictive prostanoid. 40,42 Taken together, lung vasoconstrictor responses apparently do not contribute to the leukoagglutinin-induced acute lung injury to a major extent. This is in accordance with the clinical observation that pulmonary artery pressure is only infrequently elevated in patients with TRALI.

The present experimental study corroborates repeated clinical observations that leukoagglutinating antibodies are capable of evoking severe pulmonary vascular leakage. Initiation of concomitant complement activation may contribute to the development of this injury. The subsequently formed protein-rich lung edema is known to be associated with serious disturbances of gas exchange. 43,44 The predominance of lung fluid balance alteration, not accompanied by major alterations in pulmonary hemodynamics, may explain the fact that transfusion-related lung edema is often misdiagnosed as circulatory overload. 14 The establishment of an ex vivo model of TRALI can be expected to allow further elucidation of pathogenetic events underlying the development of this severe transfusion-related incident.

ACKNOWLEDGMENT

We are grateful to Dr S. Baudner and H. Haupt, Behringwerke Marburg, FRG, for help with the purification of the IgG fraction. We thank Ch. Ernst and H. Michnass for excellent technical assistance, and P. Müller for skillful graphical illustration.

REFERENCES

21. Van Rood JJ, van Leeuwen A: Alleloigens of leucocytes and...


27. Taylor AR, Gaar KA: Calculation of equivalent pore radii of the pulmonary capillary and alveolar membranes. Argent Angiol 111:25, 1980


40. Voelkel NF: Species variations in the pulmonary responses to arachidonic acid metabolites. Prostaglandins 29:867, 1985


Reproduction of transfusion-related acute lung injury in an ex vivo lung model [see comments]

W Seeger, U Schneider, B Kreusler, E von Witzleben, D Walmrath, F Grimminger and J Neppert